Form 4: Reviva Pharmaceuticals Director Acquires Stock Options

A Reviva Pharmaceuticals director, Purav Patel, was granted stock options for 8,200 shares at an exercise price of $2.52 per share.

Summary

• Purav Patel, a director at Reviva Pharmaceuticals Holdings, Inc., was granted stock options to purchase 8,200 shares of common stock.
• The options were granted on December 10, 2024, with an exercise price of $2.52 per share.
• The options vest 100% on the one-year anniversary of the grant date, provided Mr. Patel remains a director.
• The options expire on December 9, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The granting of stock options to a director aligns their interests with the company's performance.
• The vesting period encourages long-term commitment from the director.

Industry Context

Stock option grants are a common practice for incentivizing directors and aligning their interests with shareholders in the pharmaceutical industry.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the pharmaceutical industry, similar to companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals.
• The vesting period of one year is also typical, aligning with common industry practices for incentivizing long-term commitment.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially leading to increased value.

Key Dates

Keywords

stock options, director, equity, Reviva Pharmaceuticals, insider trading, beneficial ownership